Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

This study has been completed.
Information provided by:
Vertex Pharmaceuticals Incorporated Identifier:
First received: July 27, 2004
Last updated: December 17, 2007
Last verified: December 2007